Showing results (41-50 of 302) with videos related to
Sort By:
Pageof 31
Journal of General Internal Medicine|April 16, 2020
Orphan Drugs Offer Larger Health Gains but Less Favorable Cost-effectiveness than Non-orphan DrugsJames D Chambers, Madison C Silver, Flora C Berklein, et al.Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 29, 2025
Changes in Out-of-Pocket Drug Expenditures Among Medicare Beneficiaries With Dementia Under the Inflation Reduction Act: A Simulation StudyYingying Zhu, Natalia Olchanski, Karen M Freund, et al.Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 22, 2022
The Impact of Broader Value Elements on Cost-Effectiveness Analysis: Two Case StudiesSiyu Ma, Natalia Olchanski, Joshua T Cohen, et al.Health Affairs (Project Hope)|February 4, 2015
Medicare is scrutinizing evidence more tightly for national coverage determinationsJames D Chambers, Matthew Chenoweth, Michael J Cangelosi, et al.Health Research Policy and Systems|December 4, 2016
The influence of cost-per-DALY information in health prioritisation and desirable features for a registry: a survey of health policy experts in Vietnam, India and BangladeshYot Teerawattananon, Sripen Tantivess, Inthira Yamabhai, et al.Pharmacoeconomics|July 23, 2020
Perspective and Costing in Cost-Effectiveness Analysis, 1974-2018David D Kim, Madison C Silver, Natalia Kunst, et al.Pharmacoeconomics|October 22, 2020
Correction to: Perspective and Costing in Cost‑Effectiveness Analysis, 1974-2018David D Kim, Madison C Silver, Natalia Kunst, et al.Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 23, 2025
Public HealthPatricia G Synnott, Joshua T Cohen, Theresa Frangiosa, et al.Expert Review of Pharmacoeconomics & Outcomes Research|May 16, 2017
The influence of time horizon on results of cost-effectiveness analysesDavid D Kim, Colby L Wilkinson, Elle F Pope, et al.Medical Care|January 14, 2016
Linking Costs and Survival in the Treatment of Older Adults With Chronic Myeloid Leukemia: An Analysis of SEER-Medicare Data From 1995 to 2007Pei-Jung Lin, Aaron N Winn, Susan K Parsons, et al.Pageof 31